Release date: December 1, 2006 (Accreditation Expired)
Program Description
In the management of psychotic episodes, the implications of sedation differ depending upon the intervention stage. Sedation that is advantageous in acute intervention may interfere with therapy in later stages. Historically, the sedation associated with older antipsychotic agents was considered a sign of efficacy. Recent studies, however, show that newer antipsychotic agents effectively control both psychosis and acute agitation with minimal sedation. Use of these agents may achieve acute control while allowing the patient to participate in therapeutic and normal daily activities. In this program, our experts will review the role of sedation in the management of psychotic episodes, from acute stabilization through maintenance.
Target Audience
This program will be designed specifically for psychiatrists and health care providers who treat patients with chronic mental illness.
Educational Objectives
At the conclusion of this activity, participants will be able to:
Describe the overall role of pharmacotherapy in acute stabilization of the agitated psychotic patient
Define and distinguish "sedation" and "acute control"
Evaluate methods of psychosis management, including the management of psychotic episodes
Describe how sedation impairs cognitive functioning
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Bristol-Myers Squibb Company, any other manufacturer of pharmaceuticals, the Semel Institute at UCLA, or Scinexa, LLC.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Printer settings may vary. Please use landscape layout option.
John M. Kane, MD Chairman, Dept. of Psychiatry
The Zucker Hillside Hospital Professor of Psychiatry, Neurology, and Neuroscience The Albert Einstein College of Medicine
Faculty
Christoph U. Correll, MD Medical Director, Recognition and Prevention (RAP) Program Director, Adverse Events Assessment and Prevention Unit
Advanced Center for Intervention and Services Research
The Zucker Hillside Hospital
North Shore-Long Island Jewish Health System
Assistant Professor of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Del D. Miller, PharmD, MD Professor of Psychiatry
University of Iowa Carver College of Medicine
Medical Director of Neuropsychiatric Inpatient Unit
University of Iowa Hospital and Clinics
